Edition:
India

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

81.88CHF
21 Sep 2018
Change (% chg)

CHF-0.06 (-0.07%)
Prev Close
CHF81.94
Open
CHF82.50
Day's High
CHF82.50
Day's Low
CHF81.28
Volume
13,399,681
Avg. Vol
4,411,177
52-wk High
CHF88.30
52-wk Low
CHF71.84

Select another date:

Fri, Sep 21 2018

Spark's Luxturna blindness therapy gets European panel nod

ZURICH, Sept 21 A European Medicines Agency panel recommended approval of Spark Therapeutics' gene therapy for blindness, a move that also boosts Swiss drugmaker Novartis that bought the rights to one of the world's costliest treatments outside the United States.

UPDATE 1-UK rejects adult Novartis CAR-T therapy, after 'yes' in kids

LONDON, Sept 19 Health authorities in England have rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing its use in children and young people.

Novartis links bonuses to ethics in bid to rebuild reputation

ZURICH, Sept 17 Swiss drugmaker Novartis has revealed its employees only get a bonus if they meet or exceed expectations for ethical behaviour as it seeks to address past shortcomings that have damaged its reputation.

Alcon picks Geneva over Texas for new HQ

ZURICH The headquarters of Alcon, the eyecare unit of Novartis which will be spun off to shareholders in 2019, will move from the division's longtime corporate home in the Dallas suburbs to the Swiss city of Geneva, Novartis said in a statement on Tuesday.

UPDATE 1-Alcon picks Geneva over Texas for new HQ

* Texas to remain major site for eyecare unit post spin-off (Adds detail about headquarters in Geneva, comment from CEO)

Novartis's Alcon unit to have headquarters in Geneva after spin-off

ZURICH, Sept 11 Alcon, the eyecare unit of Novartis set to be spun off into a separate company next year, plans to have its headquarters in Geneva, saying the location will help increase the business's global scale.

Swiss stocks - Factors to watch on Sept 7

ZURICH/BERLIN, Sept 7 Here are some of the main factors that may affect Swiss stocks on Friday:

Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

ZURICH/BENGALURU New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd for up to $1 billion.

UPDATE 3-Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

* Deal to result in $70 mln impairment for Novartis (Adds related content, detail about impairment in third graf, updates shares)

Novartis sells U.S. generics assets to bargain-hunting Aurobindo Pharma

ZURICH/BENGALURU New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd for up to $1 billion.

Select another date: